This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	UDP glucuronosyltransferase 2 family polypeptide B15 (UGT2B15)	Patient and cell culture studies suggest activating UGT2B15 could help treat prostate cancer. In samples from patients with prostate cancer receiving androgen deprivation therapy, UGT2B15 levels were higher than those in patients not receiving the therapy. In cultured prostate cancer cell lines, androgen receptor (AR) antagonists led to an AR-dependent decrease in UGT2B15 expression and activity compared with no treatment. Also in the cells, *UGT2B15* knockdown decreased the antiproliferative effects of AR antagonists compared with no knockdown. Next steps include finding selective activators of UGT2B15 and generating transgenic mouse models expressing human *UGT2B15*. ***SciBX*** **6(46); doi:10.1038/scibx.2013.1318** **Published online Dec. 5, 2013**	Unpatented; licensing status not applicable	Grosse, L. *et al. Cancer Res.*; published online Oct. 11, 2013; doi:10.1158/0008-5472.CAN-13-1462 **Contact:** Olivier Barbier, Laval University, Quebec City, Quebec, Canada e-mail: olivier.barbier@crchul.ulaval.ca